Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug CandidatesGlobeNewsWire · Oct 15, 2026
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal RoadshowGlobeNewsWire · Sep 3, 2026Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.